




# 11-ICML

June 15-18, 2011

Lugano, Switzerland

## 11th International Conference on Malignant Lymphoma

### POCKET PROGRAM



Organized in association with:

**Fondazione per la Ricerca e la Cura dei Linfomi**



GlaxoSmithKline  
Oncology

Printed by courtesy of

**CONFERENCE PRESIDENT:** F. Cavalli, Bellinzona (CH)

#### ORGANIZING COMMITTEE:

M. Ghielmini, Bellinzona (CH) – Chairman  
J.O. Armitage, Omaha, NE (USA)  
F.E. Cotter, London (UK)  
M.F. Fey, Berne (CH)  
R.D. Gascoyne, Vancouver, B.C. (CA)  
M.K. Gospodarowicz, Toronto (CA)  
P.W.M. Johnson, Southampton (UK)  
E. Zucca, Bellinzona (CH)

#### ADVISORY BOARD:

F. Bertoni, Bellinzona (CH)	M. Manz, Zurich (CH)
E. Campo, Barcelona (E)	E. Montserrat, Barcelona (E)
B.D. Cheson, Washington, D.C. (USA)	S.A. Pileri, Bologna (IT)
J.M. Connors, Vancouver, B.C. (CA)	A. Rosenwald, Würzburg (DE)
R. Dalla-Favera, New York, NY (USA)	J.F. San Miguel, Salamanca (E)
M. Dreyling, Munich (DE)	J.F. Seymour, Melbourne (AU)
J.W. Friedberg, Rochester, NY (USA)	M.A. Shipp, Boston, MA (USA)
G. Gaidano, Novara (IT)	L.M. Staudt, Bethesda, MD (USA)
N.L. Harris, Boston, MA (USA)	H. Stein, Berlin (DE)
S.J. Horning, Stanford, CA (USA)	C. Thieblemont, Paris (FR)
E.S. Jaffe, Bethesda, MD (USA)	K. Tobinai, Tokyo (JP)
J.P. Leonard, New York, NY (USA)	U. Vitolo, Turin (IT)
T.A. Lister, London (UK)	D.D. Weisenburger, Omaha NE (USA)
A. Lopez-Guillermo, Barcelona (E)	

#### 11-ICML Secretariat

IOSI, Ospedale San Giovanni

CH - 6500 Bellinzona

Tel. 0041 (0)91 922 0575

Fax 0041 (0)91 922 2084

[www.lymphcon.ch](http://www.lymphcon.ch)

C. Brentan [cristiana.brentan@lymphcon.ch](mailto:cristiana.brentan@lymphcon.ch)

O. Lugli [oretta.lugli@lymphcon.ch](mailto:oretta.lugli@lymphcon.ch)

C. Saporiti [registration@lymphcon.ch](mailto:registration@lymphcon.ch)

## Sunday, June 12 – Tuesday, June 14, 2011

### LEUKAEMIA AND LYMPHOMA

2011 European School of Oncology (ESO) Advanced Course

Location: Monte Verità, Ascona (CH)

Chairmen: M.F. Fey, Berne (CH), J.M. Connors, Vancouver, B.C. (CA) and F. Cavalli, Bellinzona (CH)

## Tuesday, June 14, 2011

- 08:30 Opening of the registration desk
- 08:30 – 17:00 **WORKSHOP: "LYMPHOMA PRETREATMENT ASSESSMENT AND RESPONSE CRITERIA IN THE NEW MILLENNIUM: BEYOND ANN ARBOR" \*** (Closed - USI Auditorium, Lugano University)  
Steering Committee: B.D. Cheson, Washington, D.C. (USA), R.I. Fisher, Rochester, NY (USA), T.A. Lister, London (UK), E. Zucca, Bellinzona (Switzerland)  
*\*organized with the financial support of European School of Oncology (ESO) and European Society of Medical Oncology (ESMO)*
- 13:00 – 15:00 (parallel symposia) **PFIZER**  
**OPEN TOPICS IN MANTLE CELL LYMPHOMA : CASE DISCUSSION AND STATE OF THE ART** (room B I)  
Chair : M. Ghilmini, Bellinzona (Switzerland)
- MUNDIPHARMA / GLAXOSMITHKLINE**  
**CHEMOIMMUNOTHERAPY: SHAPING THE FUTURE OF NHL MANAGEMENT** (room B II)  
Chair : J. Friedberg, Rochester (USA)
- 16:00 – 18:00 (parallel symposia) **prIME Oncology**  
**HOW I TREAT HEMATOLOGIC MALIGNANCY IN 2011: EXPERT GUIDANCE FOR THE CLINICIAN** (room A)  
Chair : J. O. Armitage, Omaha, NE (United States)
- JANSSEN**  
**RECENT ADVANCES IN THE MANAGEMENT OF FOLLICULAR LYMPHOMA AND OTHER HEMATOLOGICAL MALIGNANCIES (part 1)** (room B II)  
Chair : P.L. Zinzani, Bologna (Italy)
- 19:00 – 21:00 (parallel symposia, except for\*) **F. HOFFMANN-LA ROCHE LIMITED**  
**MANAGEMENT OF B-CELL MALIGNANCIES TODAY: A LONG-TERM PERSPECTIVE** (room A)  
Chair : F. Cavalli, Bellinzona (Switzerland)
- NOVARTIS**  
**ADDRESSING THE UNMET CLINICAL NEED IN MALIGNANT LYMPHOMA THROUGH NOVEL AGENTS** (room BI)
- JANSSEN**  
**RECENT ADVANCES IN THE MANAGEMENT OF FOLLICULAR LYMPHOMA AND OTHER HEMATOLOGICAL MALIGNANCIES (part 2)\*** (room B II) \* 18:30 – 20:30  
Chair : P.L. Zinzani, Bologna (Italy)

## CONFERENCE SCHEDULE

### Wednesday, June 15, 2011

---

- 08:00 – 08:45 Article/abstract IX **MEET THE PROFESSOR - (6 parallel sessions)**  
CLL FOR THE CLINICIAN (room A)  
M. Hallek, Cologne (Germany)
- I EPIDEMIOLOGY OF ADULT NON-HODGKIN LYMPHOMA (room B I)  
P. Boffetta, New York NY (USA)
- XIII THE ROLE OF IMMUNOTHERAPY IN THE TREATMENT OF LYMPHOMA (room B II)  
R. Levy, Stanford, CA (USA)
- VII THE ROLE OF THE MICROENVIRONMENT IN LYMPHOID CANCERS (USI Auditorium, Lugano University)  
R.D. Gascoyne, Vancouver, B.C. (Canada)
- V PRIMARY CNS LYMPHOMA IN IMMUNOCOMPETENT PATIENTS (USI Aula Magna, Lugano University)  
A.J. Ferreri, Milan (Italy)
- VIII RADIO-IMMUNOTHERAPY IN MALIGNANT LYMPHOMA: AN UNDERUSED TOOL? (Cittadella Theater)  
A. Hagenbeek, Amsterdam (Netherlands)
- 09:00 – 09:45 **MEET THE PROFESSOR - (6 parallel sessions)**
- VI MICRO-ARRAYS FOR DUMMIES (room A)  
M.F. Fey, Berne (Switzerland)
- XV PRIMARY CUTANEOUS LYMPHOMAS (room B I)  
R. Willemze, Leiden (Netherlands)
- XII GRAY ZONE LYMPHOMAS: A BIOLOGICAL EXPERIMENT, AND A CHALLENGE FOR DIAGNOSIS AND MANAGEMENT (room B II)

		E.S. Jaffe, Bethesda, MD (USA)
	IV	EPIGENETICS : WHAT IT IS AND WHAT IT CAN BRING (USI Auditorium, Lugano University) M. Esteller, L'Hospitalet de Llobregat - Barcelona (Spain)
	III	ROLE OF ALLOTRANSPLANTATION FOR NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA (USI Aula Magna, Lugano University) P. Dreger, Heidelberg (Germany)
	X	WHEN SHOULD RADIOTHERAPY BE USED IN LYMPHOMA? (Cittadella Theater) T. Illidge, Manchester (UK)
10:00 – 10:45		<b>MEET THE PROFESSOR</b> (6 parallel sessions)
	II	NEW PERSPECTIVES AND CHALLENGES IN THE UNDERSTANDING OF MANTLE CELL LYMPHOMA (room A) E. Campo, Barcelona (Spain)
	XIV	T AND NK CELL LYMPHOPROLIFERATIVE DISORDERS (room B I) S.T. Rosen, Chicago, IL (USA)
	XI	DISTINGUISHING BURKITT LYMPHOMA FROM DIFFUSE LARGE B-CELL LYMPHOMA (room B II) A. Jack, Leeds (UK)
	IV	EPIGENETICS : WHAT IT IS AND WHAT IT CAN BRING (USI Auditorium, Lugano University) M. Esteller, L'Hospitalet de Llobregat - Barcelona (Spain)
	V	PRIMARY CNS LYMPHOMA IN IMMUNOCOMPETENT PATIENTS (USI Aula Magna, Lugano University) A.J. Ferreri, Milan (Italy)
	VIII	RADIO-IMMUNOTHERAPY IN MALIGNANT LYMPHOMA: AN UNDERUSED TOOL? (Cittadella Theater) A. Hagenbeek, Amsterdam (Netherlands)
11:00 – 12:00		<b>CONTROVERSY I : CONTROVERSIES IN FOLLICULAR LYMPHOMAS</b> (room A, B, C and Marquee Parco Ciani) Chair : T. A. Lister, London (UK)
004 - 005		a) A TREATMENT IS NECESSARY IN FL: SHOULD WE START WITH R-CT OR IS RITUXIMAB ALONE SUFFICIENT? R.I. Fisher, Rochester, NY (USA) vs M. Ghielmini, Bellinzona (Switzerland)
006 - 007		b) MAINTENANCE IN FL: RIT OR RITUXIMAB? A. Hagenbeek, Amsterdam (Netherlands) vs E. Kimby, Stockholm (Sweden)
12:00 – 13:00		<b>LUNCH TIME</b> (Marquee Parco Ciani)
13:00 – 13:55		<b>OPENING OF THE CONFERENCE</b> (room A, B, C and Marquee Parco Ciani) Chair : F. Cavalli, Bellinzona (Switzerland)
13:00		<b>WELCOME AND INTRODUCTORY REMARKS</b> F. Cavalli, Bellinzona (Switzerland)
13:10		<b>AWARD OF THE SAN SALVATORE FOUNDATION</b> combined with HENRY KAPLAN MEMORIAL LECTURE Introduction to the Foundation: L. Butti, Lugano (Switzerland) President of the Foundation Presentation of the award : R.A. Stahel, Zurich (Switzerland), Chairman of the Scientific Committee
13:20	001	<b>HENRY KAPLAN MEMORIAL LECTURE</b> (room A, B, C and Marquee Parco Ciani) MOLECULAR PATHOGENESIS OF B CELL LYMPHOMAS: FROM CYTOGENETICS TO GENOME SEQUENCING R. Dalla-Favera, New York, NY (USA)
14:00 - 14:45		<b>SESSION 1 – LYMPHOMA EPIDEMIOLOGY</b> (room A, B, C and Marquee Parco Ciani) Chair: D.D. Weisenburger, Omaha NE (USA)
14:00	008	PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) CONTINUES TO INCREASE AMONG OLDER ( $\geq 65$ YEARS OF AGE) PATIENTS IN THE UNITED STATES (US) BUT NOT AMONG YOUNGER (20-64 YEARS OF AGE) PATIENTS. A SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER) STUDY B.P. O'Neill et al., Rochester, MN (USA)
14:15	009	PREVALENCE AND FREQUENCY OF CIRCULATING T(14;18)-POSITIVE CELLS IN HEALTHY INDIVIDUALS OF A POPULATION-BASED CROSS SECTIONAL STUDY – ASSOCIATION WITH AGE AND GENDER BUT NOT WITH SMOKING STATUS C. Hirt et al., Greifswald (Germany)
14:30	010	A COMPREHENSIVE ANALYSIS OF THE UNITED STATES (US) HODGKIN LYMPHOMA (HL) SEER DATABASE: THE IMPACT OF RACE AND PLACE OF BIRTH ON INCIDENCE AND SURVIVAL A.M. Evens et al., Worcester, MA (USA)
14:45 – 15:05		<b>COFFEE BREAK</b> (Marquee Parco Ciani)
15:05 - 16:10		<b>SESSION 2 - LYMPHOMA AND ITS MICROENVIRONMENT</b> (room A, B, C and Marquee Parco Ciani) Chair: R.D. Gascoyne, Vancouver, B.C. (CA)
15:05	011	Introductory lecture: R.D. Gascoyne, Vancouver, B.C. (CA)
15:25	012	DEFECTS AND ABNORMALITIES IN INFILTRATING T CELLS IN PATIENTS WITH FOLLICULAR LYMPHOMA AT DIAGNOSIS S. Kiaii et al., London (UK)
15:40	013	RITUXIMAB INFUSION INDUCES NK ACTIVATION IN LYMPHOMA PATIENTS WITH THE HIGH AFFINITY CD16 POLYMORPHISM G. Weiner et al., Iowa City, IA (USA)

15:55	014	AMD3100 DISRUPTS THE CROSS-TALK BETWEEN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND THEIR MICROENVIRONMENT: PRECLINICAL EVIDENCE FOR ITS COMBINATION WITH CLL TREATMENTS B. Stamatopoulos et al., Brussels (Belgium)
16:10 – 17:10		<b>SESSION 3 – MANTLE CELL LYMPHOMA</b> (room A, B, C and Marquee Parco Ciani) Chair : M. Dreyling, Munich (Germany) and M.F. Fey, Berne (Switzerland)
16:10	015	DIFFERENTIAL EXPRESSION OF SOX11, HDGFRP3, AND DBN1 IDENTIFIES TWO SUBGROUPS OF MCL WITH DIFFERENT CLINICAL OUTCOME AND GENETIC FEATURES C. Royo et al., Barcelona (Spain)
16:25	016	R-CHOP VERSUS R-FC FOLLOWED BY MAINTENANCE WITH RITUXIMAB OR IFN: FIRST RESULTS OF A RANDOMIZED TRIAL FOR ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA J.C. Kluin-Nelemans et al., Groningen (Netherlands)
16:40	017	PHASE II STUDY OF R-CHOP FOLLOWED BY <sup>90</sup> Y-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499 M.R. Smith et al., Philadelphia, PA (USA)
16:55	018	OUTCOME OF PATIENTS WITH MANTLE CELL LYMPHOMA UNDERGOING AUTOLOGOUS VERSUS REDUCED-INTENSITY ALLOGENEIC TRANSPLANTATION T.S. Fenske et al., Milwaukee, WI (USA)
17:30 – 18:30		<b>FOCUS ON... SESSIONS</b> (6 parallel sessions)
17:30 – 18:30		<b>UPDATE OF RANDOMISED TRIALS</b> (room A) Chair : R.I. Fisher, Rochester, NY (USA)
17:30	019	PRELIMINARY RESULTS OF QUALITY OF LIFE (QOL) ANALYSES FROM THE INTERGROUP PHASE III RANDOMISED TRIAL OF RITUXIMAB VS A WATCH AND WAIT APPROACH IN PATIENTS WITH ADVANCED STAGE, ASYMPTOMATIC, NON-BULKY FOLLICULAR LYMPHOMA (FL) K.M. Ardeshna et al., London (UK)
17:40	020	IMPROVED SURVIVAL AFTER A MEDIAN FOLLOW-UP OF 6 YEARS FOR IMMUNOCHEMOTHERAPY (R-MCP) VERSUS CHEMOTHERAPY ALONE (MCP) IN ADVANCED FOLLICULAR LYMPHOMA (FL) - UPDATE OF THE OSHO#39 TRIAL M. Herold et al., Erfurt (Germany)
17:50	021	<i>EIGHT-YEAR FOLLOW-UP</i> OF THE GELA-GOELAMS FL2000 STUDY COMPARING CHVP-INTERFERON TO CHVP-INTERFERON PLUS RITUXIMAB IN FOLLICULAR LYMPHOMA PATIENTS E. Bachy et al., Lyon (France)
18:00	022	IMPACT OF INDUCTION CHEMOTHERAPY REGIMEN ON RESPONSE, SAFETY AND OUTCOME IN THE PRIMA STUDY F. Morschhauser et al., Lille (France)
18:10	023	ALTERNATING COURSES OF 3X CHOP AND 3X DHAP PLUS RITUXIMAB FOLLOWED BY A HIGH DOSE ARA-C CONTAINING MYELOABLATIVE REGIMEN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IS SUPERIOR TO 6 COURSES OF CHOP PLUS RITUXIMAB FOLLOWED BY MYELOABLATIVE RADIOCHEMOTHERAPY AND ASCT IN MANTLE CELL LYMPHOMA: UPDATE OF RESULTS OF THE MCL YOUNGER TRIAL OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK ( <i>MCL NET</i> ) O.R. Hermine et al., Paris (France)
18:20	024	SURVIVAL IMPACT OF DARBEPOETIN ALFA IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH IMMUNOCHEMOTHERAPY: THE LNH03-6B GELA STUDY R. Delarue et al., Paris (France)
17:30 - 18:30		<b>RADIOTHERAPY AND EARLY STAGE</b> (room B I) Chair : M.K. Gospodarowicz, Toronto (CA)
17:30	025	RADIATION DOSE FOR LOCAL CONTROL IN NON-HODGKIN LYMPHOMA L: BRITISH NATIONAL LYMPHOMA INVESTIGATION RANDOMISED TRIAL P. Hoskin et al., Northwood (UK)
17:40	026	SHOULD RADIATION THERAPY (XRT) BE THE STANDARD THERAPEUTIC APPROACH FOR STAGE I FOLLICULAR LYMPHOMA (FL)? A COMPARATIVE EFFECTIVENESS ANALYSIS OF THE NATIONAL LYMPHOCARE STUDY (NLCS) J.W. Friedberg et al., Rochester, NY (USA)
17:50	027	FOLLICULAR LYMPHOMA: CURABILITY BY RADIOTHERAPY IN LIMITED STAGE NODAL DISEASE? UPDATED RESULTS OF A RANDOMIZED TRIAL M. Engelhard et al., Essen (Germany)
18:00	028	TREATMENT OF LIMITED-STAGE DLBCL CAN BE EFFECTIVELY TAILORED USING A PET-BASED APPROACH L.H. Sehn et al., Vancouver, B.C. (Canada)
18:10	029	6-YEAR FOLLOW-UP OF THE MINT STUDY SUGGESTS A ROLE FOR RADIOTHERAPY TO BULKY DISEASE M. Pfreundschuh et al., Homburg (Germany)
18:20	030	ACVBP VERSUS ACVBP PLUS RITUXIMAB FOR YOUNG PATIENTS WITH LOCALIZED LOW-RISK DIFFUSE LARGE B-CELL LYMPHOMA: A STUDY BY THE GROUPE D'ETUDE DES LYMPHOMES DE L'ADULTE N. Ketterer et al., Lausanne (Switzerland)
17:30 – 18:30		<b>PRIMARY CNS LYMPHOMA</b> (room B II) Chair : A.J. Ferreri, Milan (Italy)
17:30	031	IMPACT OF MENINGEAL DISSEMINATION (MD) ON OUTCOME IN PRIMARY CNS LYMPHOMA IN THE G-PCNSL-SG1 TRIAL

A. Korfel et al., Berlin (Germany)

- 17:40 032 IS PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) REALLY RESTRICTED TO THE CNS? EVALUATION OF SUBCLINICAL SYSTEMIC INVOLVEMENT WITH PCR  
K. Jahnke et al., Berlin (Germany)
- 17:50 033 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION AS FIRST-LINE TREATMENT FOR PRIMARY CNS LYMPHOMA - UPDATED RESULTS OF A PILOT AND PHASE II STUDY  
E. Schorb et al., Freiburg (Germany)
- 18:00 034 IMMUNOCHEMOTHERAPY WITH INTENSIVE CONSOLIDATION, WITHOUT BRAIN IRRADIATION, FOR PRIMARY CNS LYMPHOMA: A PILOT STUDY WITH PROGNOSTIC ASSESSMENT BY DIFFUSION-WEIGHTED MRI  
J.L. Rubenstein et al., San Francisco, CA (USA)
- 18:10 035 INTENSIVE CHEMOTHERAPY WITH THIOTEPA, BUSULFAN, AND CYCLOPHOSPHAMIDE (TT-BU-CY) WITH HEMATOPOIETIC STEM CELL RESCUE (IC + HCR) IN RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) OR INTRAOCULAR LYMPHOMA (IOL): A RETROSPECTIVE STUDY OF 74 CASES  
C. Soussain et al., Saint-Cloud (France)
- 18:20 036 LONG-TERM COGNITIVE OUTCOME IN PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL): A TRANS-ATLANTIC MULTI-CENTER STUDY  
N.D. Doolittle et al., Portland, OR (USA)
- 17:30 – 18:30 **ALLOGENEIC TRANSPLANTATION** (USI Auditorium, Lugano University)  
Chair : P. Dreger, Heidelberg (Germany)
- 17:30 037 RISK FACTOR ANALYSIS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR FOLLICULAR LYMPHOMA (FL). A RETROSPECTIVE STUDY ON BEHALF OF THE EBMT (THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION) LYMPHOMA WORKING PARTY AND THE CIBMTR (CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH) LYMPHOMA WORKING COMMITTEE  
A. Sureda et al., Cambridge (UK)
- 17:40 038 ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) PROGRESSING AFTER AUTOLOGOUS TRANSPLANTATION (AUTOHCT). *ON BEHALF OF THE WRITING COMMITTEE, CENTER FOR INTERNATIONAL BLOOD & MARROW TRANSPLANT RESEARCH (CIBMTR), MEDICAL COLLEGE OF WISCONSIN, MILWAUKEE, WI*  
P.N. Hari et al., Milwaukee, WI (USA)
- 17:50 039 REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: THE EBMT EXPERIENCE  
S.P. Robinson et al., Bristol (UK)
- 18:00 040 ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED OR CHEMOREFRACTORY T-CELL LYMPHOMA: ROLE OF HIGH INTENSITY CONDITIONING  
B. Glass et al., Hamburg (Germany)
- 18:10 041 HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR EXTRANODAL NK/T-CELL LYMPHOMA, NASAL-TYPE: THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION (JSHCT) LYMPHOMA WORKING PARTY  
R. Suzuki et al., Nagoya (Japan)
- 18:20 042 BENDAMUSTINE IN COMBINATION WITH FLUDARABINE AND RITUXIMAB: A PHASE I-II NOVEL NONMYELOABLATIVE CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION (AST) IN PATIENTS WITH LYMPHOID MALIGNANCIES  
I.F. Khouri et al., Houston, TX (USA)
- 17:30 – 18:30 **PET USE IN LYMPHOMA** (USI Aula Magna, Lugano University)  
Chair : T.A. Lister, London (UK)
- 17:30 043 IS MARROW BIOPSY STAGING FOR HD AND DLBCL OBSOLETE IN THE PET-CT ERA?  
A.B. Khan et al., London (UK)
- 17:40 044 THE GERMINAL CENTER B-CELL SIGNATURE IS ASSOCIATED TO A HIGHER [<sup>18</sup>F]-FDG UPTAKE AND IMPROVES THE PROGNOSIS VALUE OF PET SCAN IN DIFFUSE LARGE B-CELL LYMPHOMAS (DLBCL) TREATED BY RITUXIMAB (R) AND ANTHRACYCLINES-BASED CHEMOTHERAPY  
F. Jardin et al., Rouen (France)
- 17:50 045 FDG-PET TO GUIDE RADIOTHERAPY IN ADVANCED-STAGE HODGKIN LYMPHOMA PATIENTS WITH RESIDUAL BULKY DISEASE AFTER CHEMOTHERAPY: RESULTS OF THE GHSG HD15 TRIAL  
A. Engert et al., Cologne (Germany)
- 18:00 046 PET-CT OF FOLLICULAR LYMPHOMA IN PATIENTS TREATED IN THE PRIMA STUDY: CENTRAL REVIEW OF SCANS USING THE 5PS  
C. Tychyj-Pinel et al., Pierre Bénite (France)
- 18:10 047 INTERNATIONAL VALIDATION STUDY OF INTERPRETATION RULES AND PROGNOSTIC ROLE OF INTERIM-PET SCAN IN ADVANCED STAGE HODGKIN LYMPHOMA  
A. Gallamini et al., Cuneo (Italy)
- 18:20 048 CLINICAL USEFULNESS AND PROGNOSTIC SIGNIFICANCE OF INTERIM <sup>18</sup>F-FDG PET/CT FOR THE TREATMENT OF PERIPHERAL T CELL LYMPHOMAS  
D.H. Yang et al., Jeollanam-do (Republic of Korea)
- 17:30 – 18:30 **IMMUNODEFICIENCY AND LYMPHOMA** (Cittadella Theater)  
Chair : M. Ponzoni, Milan (Italy)
- 17:30 049 GENOMIC COPY NUMBER ABERRATIONS (CNA) AFFECTING THE OUTCOME OF IMMUNODEFICIENCY-RELATED DIFFUSE

		LARGE B-CELL LYMPHOMAS (ID-DLBCL) F. Bertoni et al., Bellinzona (Switzerland)
17:40	050	METHYLOME PROFILING OF POST-TRANSPLANT DIFFUSE LARGE B-CELL LYMPHOMAS (PT-DLBCL) D. Capello et al., Novara (Italy)
17:50	051	EBV-POSITIVE AND EBV-NEGATIVE POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS: TWO DIFFERENT DISORDERS? T. Tousseyn et al., Leuven (Belgium)
18:00	052	THE ACCURACY OF PET IN THE DETECTION OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) D. Dierickx et al., Leuven (Belgium)
18:10	053	ADAPTED MANAGEMENT OF EBV REACTIVATION AFTER SOLID ORGAN TRANSPLANTATION: AN EFFECTIVE PREVENTION OF POST TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS (PTLD)? RESULTS OF THE LARGEST PROSPECTIVE STUDY ON 251 PATIENTS, AND COMPARISON WITH 820 TRANSPLANTED CONTROLS S. Choquet et al., Paris (France)
18:20	054	PRIMARY CENTRAL NERVOUS SYSTEM (CNS) POST-TRANSPLANT LYMPHOPROLIFERATION (PTLD): AN INTERNATIONAL REPORT OF 52 CASES IN THE RITUXIMAB ERA A.M. Evens et al., Worcester, MA (USA)
19:00 – 21:00 (symposium)		MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY <b>EMERGING TREATMENT STRATEGIES IN CD30-EXPRESSING LYMPHOMAS</b> (room B I) Chair: A. Engert, Cologne (Germany)

## Thursday, June 16, 2011

---

08:00 – 08:30		POSTER SET UP I (Marquee Parco Ciani)
08:30 – 18:30		<b>POSTER SESSION I*</b> (Marquee Parco Ciani) *printing of the posters sponsored by Mundipharma <i>Authors present during lunch time</i>
	167-171	EPIDEMIOLOGY
	172-186	BIOLOGY
	187-202	GENOMICS
	203-214	PATHOLOGY AND CLINICOPATHOLOGICAL CORRELATIONS
	215-229	PET
	230-239	MCL
	240-249	T-CELL
	250-259	AUTOLOGOUS TRANSPLANTATION
	260-269	CLL
08:00 - 08:45		<b>MEET THE PROFESSOR</b> (repetition of some of Wednesday sessions)
	IX	CLL FOR THE CLINICIAN (room A) M. Hallek, Cologne (Germany)
	I	EPIDEMIOLOGY OF ADULT NON-HODGKIN LYMPHOMA (room B I) P. Boffetta, New York, NY (USA)
	XII	GRAY ZONE LYMPHOMAS: A BIOLOGICAL EXPERIMENT, AND A CHALLENGE FOR DIAGNOSIS AND MANAGEMENT (room B II) E.S. Jaffe, Bethesda, MD (USA)
	II	NEW PERSPECTIVES AND CHALLENGES IN THE UNDERSTANDING OF MANTLE CELL LYMPHOMA (USI Auditorium, Lugano University) E. Campo, Barcelona (Spain)
	III	ROLE OF ALLOTRANSPLANTATION FOR NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA (USI Aula Magna, Lugano University) P. Dreger, Heidelberg (Germany)
	X	WHEN SHOULD RADIOTHERAPY BE USED IN LYMPHOMA? (Cittadella Theater) T. Illidge, Manchester (UK)
09:00 - 10:35		<b>SESSION 4 - LYMPHOMA GENOMICS</b> (room A and Marquee Parco Ciani) Chair : R. Dalla-Favera, New York, NY (USA) and R. Siebert, Kiel (Germany)
09:00	055	Introductory lecture: R. Siebert, Kiel (Germany)
09:20	056	FUNCTIONAL CHARACTERIZATION OF AN 11Q24.3 GAIN CONTRIBUTING TO THE PATHOGENESIS OF DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY BLOCKING B-CELL MATURATION P. Bonetti et al., Bellinzona (Switzerland)
09:35	057	PRDM1 IS A TUMOR SUPPRESSOR GENE IN NATURAL KILLER CELL MALIGNANCIES W.C. Chan et al., Omaha, NE (USA)
09:50	058	IDENTIFICATION OF FOXO3 AND PRDM1 AS TUMOR SUPPRESSOR GENE CANDIDATES IN NK CELL NEOPLASMS BY THE COMBINATION OF GENOMIC AND FUNCTIONAL ANALYSES K. Karube et al., Nagoya (Japan)
10:05	059	IDENTIFICATION OF A "DELETION BLOCK" AT 13Q14 THAT PERTURBS MULTIPLE SIGNALING AND SURVIVAL PATHWAYS IN PRIMARY CLASSICAL HODGKIN LYMPHOMA B. Chapuy et al., Boston, MA (USA)

10:20	060	NEXT GENERATION SEQUENCING REVEALS GENES INVOLVED IN HISTONE MODIFICATION ARE FREQUENTLY MUTATED IN NON-HODGKIN LYMPHOMA R.D. Gascoyne et al., Vancouver, B.C. (Canada)
09:00-10:30		<b>"CASE DISCUSSION" SESSIONS</b> (3 parallel sessions: room B I, B II, USI Auditorium)  HODGKIN LYMPHOMA (room B I) Chair: C. Moskowitz, New York, NY (USA) – Presenter: D. Villa, Vancouver, B.C. (Canada) Discussants: V. Diehl, Cologne (Germany) and T. Illidge, Manchester (UK)  T-CELL (room B II) Chair: S.T. Rosen, Chicago, IL (USA) – Presenter: R. Klasa, Vancouver, B.C. (Canada) Discussants: P.L. Zinzani, Bologna (Italy) and J.M. Vose, Omaha, NE (USA)  CLL (USI Auditorium, Lugano University) Chair: G. Gaidano, Novara (Italy) – Presenter: A.P. Kater, Amsterdam (Netherlands) Discussants: E. Montserrat, Barcelona (Spain) and S. Stilgenbauer, Ulm (Germany)
10:35-10:55		<b>COFFEE BREAK</b> (Marquee Parco Ciani)
10:55-12:00		<b>SESSION 5 – LYMPHOMA AND THE IMMUNE SYSTEM</b> (room A, B, C and Marquee Parco Ciani) Chair: F. Stevenson, Southampton (UK)
10:55	061	Introductory lecture: F. Stevenson, Southampton (UK)
11:15	062	IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS J. Brody et al., Stanford, CA (USA)
11:30	063	A PHASE II STUDY OF CT-011, AN ANTI-PD-1 ANTIBODY, AFTER AUSCT IN RECURRENT/REFRACTORY DLBCL: FIRST ANALYSIS OF PROGRESSION-FREE-SURVIVAL (PFS), OVERALL SURVIVAL (OS) AND TOXICITY (TOX) L. Gordon et al., Chicago, IL (USA)
11:45	064	PROMISING RESULTS OF AN ANTI-CCR4 ANTIBODY, KW-0761, FOR RELAPSED ADULT T-CELL LEUKEMIA-LYMPHOMA (ATL) K. Tobinai et al., Tokyo (Japan)
12:00-13:00		<b>LUNCH AND POSTER VIEWING</b> (Marquee Parco Ciani)
13:00-13:50	002	<b>RAPPAPORT LECTURE</b> (room A, B, C and Marquee Parco Ciani) MODELING HUMAN LYMPHOMAGENESIS IN MICE K. Rajewsky, Boston, MA (USA) Chair: B.N. Nathwani, Los Angeles, CA (USA)
13:55-15:30		<b>SESSION 6 - TARGETING THE LYMPHOMA CELL SURFACE</b> (room A, B, C and Marquee Parco Ciani) Chair : P.W.M. Johnson, Southampton (UK) and J.P. Leonard, New York, NY (USA)
13:55	065	Introductory lecture: P.W.M. Johnson, Southampton (UK)
14:15	066	RESULTS FROM A PHASE I/II STUDY (BO20999) OF RO5072759 (GA101) MONOTHERAPY IN RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA G. Salles et al., Pierre Bénite (France)
14:30	067	ANTI-CD40 MONOCLONAL ANTIBODY LUCATUMUMAB EXHIBITS ANTI-TUMOR ACTIVITY IN FOLLICULAR LYMPHOMA AND OTHER LYMPHOMA SUBTYPES: PHASE I/II PRELIMINARY FINDINGS A. Freedman et al., Boston, MA (USA)
14:45	068	BLINATUMOMAB (CD3/CD19 BITE® ANTIBODY) RESULTS IN A HIGH RESPONSE RATE IN PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) INCLUDING MCL AND DLBCL M. Goebeler et al., Würzburg (Germany)
15:00	069	INOTUZUMAB OZOGAMICIN (INO, CMC-544) IN PTS WITH INDOLENT B-CELL NHL REFRACTORY TO RITUXIMAB (R), R PLUS CHEMOTHERAPY, OR RADIOIMMUNOTHERAPY (RIT) A. Goy et al., Hackensack, NJ (USA)
15:15	070	PHASE I/II STUDY OF THE ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE SAR3419 ADMINISTERED WEEKLY TO PATIENTS (PTS) WITH RELAPSED / REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA (NHL) B. Coiffier et al., Pierre Bénite (France)
15:30-15:50		<b>COFFEE BREAK</b> (Marquee Parco Ciani)
15:50-17:20		<b>SESSION 7 – AGGRESSIVE LYMPHOMA</b> (room A and Marquee Parco Ciani) Chair: M. Pfreundschuh, Homburg (Germany) and L.H. Sehn, Vancouver, B.C. (Canada)
15:50	071	MYC + AGGRESSIVE-B-CELL LYMPHOMAS: NOVEL THERAPY OF UNTREATED BURKITT LYMPHOMA (BL) AND MYC + DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WITH DA-EPOCH-R K. Dunleavy et al., Bethesda, MD (USA)
16:05	072	A RANDOMIZED MULTICENTRE PHASE III STUDY FOR FIRST LINE TREATMENT OF YOUNG PATIENTS WITH HIGH RISK (AAPI 2-3) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RITUXIMAB (R) PLUS DOSE-DENSE CHEMOTHERAPY CHOP14/MEGACHOP14 WITH OR WITHOUT INTENSIFIED HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT). RESULTS OF DLCL04 TRIAL OF ITALIAN LYMPHOMA FOUNDATION (FIL) U. Vitolo et al., Turin (Italy)

16:20	073	CONVENTIONAL CHEMOIMMUNOTHERAPY (R-CHOEP-14) OR HIGH-DOSE THERAPY (R-MEGA-CHOEP) FOR YOUNG, HIGH-RISK PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: FINAL RESULTS OF THE RANDOMIZED MEGA-CHOEP-TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL) N. Schmitz et al., Hamburg (Germany)
16:35	074	RANDOMIZED PHASE II STUDY OF R-CHOP PLUS ENZASTAURIN VERSUS R-CHOP IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – PRELIMINARY ANALYSIS J.D. Hainsworth et al., Nashville, TN (USA)
16:50	075	SALVAGE REGIMEN WITH AUTOLOGOUS STEM CELL TRANSPLANTATION WITH OR WITHOUT RITUXIMAB MAINTENANCE FOR RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): CORAL FINAL REPORT C. Gisselbrecht et al., Paris (France)
17:05	076	AUTOLOGOUS STEM CELL TRANSPLANTATION REMAINS BENEFICIAL FOR PATIENTS RELAPSING AFTER R-CHOP AND WHO RESPOND TO SALVAGE CHEMOTHERAPY S. Moore et al., London (UK)
15:50-18:30		<b>SESSION 8 – PATHOLOGY &amp; CLINICOPATHOLOGICAL CORRELATIONS</b> (room B) Chair: E.S. Jaffe, Bethesda, MD (USA) and S.A. Pileri, Bologna (IT)
15:50	077	THE RELIABILITY OF IMMUNOHISTOCHEMICAL ANALYSIS OF TUMOR MICROENVIRONMENT IN FOLLICULAR LYMPHOMA; A VALIDATION STUDY FROM THE LUNENBURG LYMPHOMA BIOMARKER CONSORTIUM (LLBC) D. De Jong et al., Amsterdam (Netherlands)
16:05	078	DEVELOPMENT AND APPLICATION OF A NEW IMMUNOPHENOTYPIC ALGORITHM FOR MOLECULAR CLASSIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): REPORT FROM AN INTERNATIONAL DLBCL RITUXIMAB-CHOP CONSORTIUM PROGRAM STUDY C. Visco et al., Vicenza (Italy)
16:20	079	DIFFERENTIAL GENE EXPRESSION PATTERNS IN EXTRANODAL SUBSETS OF NON-GCB DIFFUSE LARGE B-CELL LYMPHOMA T.M. Green et al., Odense (Denmark)
16:35	080	GENE EXPRESSION PROFILING (GEP) AND NOT IMMUNOCHEMICAL ALGORITHMS PREDICTS PROGNOSIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP G. Gutiérrez et al., Barcelona (Spain)
16:50	081	CONCURRENT BCL2 AND MYC TRANSLOCATIONS IN A PROSPECTIVE COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA A.O. Gang et al., Herlev (Denmark)
17:05	082	THE COMBINATION OF STAT3, CSE1L AND MYC-TRANSLOCATION FORMS A NEW DIAGNOSTIC ALGORITHM WHICH DISTINGUISHES BURKITT FROM DIFFUSE LARGE B-CELL LYMPHOMA AND PREDICTS OUTCOME M. Tinguely et al., Zurich (Switzerland)
17:20	083	OCCURRENCE OF THE T(14;18)(Q32;Q21) AND ITS VARIANTS IN CHRONIC B-CELL LYMPHOPROLIFERATIVE DISORDERS OTHER THAN FOLLICULAR LYMPHOMA L. Baseggio et al., Pierre Bénite (France)
17:35	084	INTEREST OF T(14;18) DETECTION FOR THE MANAGEMENT OF FOLLICLE CENTER LYMPHOMA PRESENTING AS SKIN LESIONS: 53 CASES STUDY A. Pham-Ledard et al., Bordeaux (France)
17:50	085	<i>BCL2</i> , <i>BCL6</i> , <i>MYC</i> , <i>CCND1</i> , <i>MALT1</i> AND <i>BCL10</i> GENE REARRANGEMENTS IN PRIMARY TESTICULAR LYMPHOMAS DETECTED BY FLUORESCENT IN SITU HYBRIDIZATION WITH SPLIT SIGNAL PROBES S. Uccella et al., Varese (Italy)
18:05	086	TISSUE MICROARRAY IN DLBCL PATIENTS RECEIVING CHOP-R CHEMO-IMMUNOTHERAPY SHOWS SURVIVAL BENEFIT FOR COEXPRESSION OF LMO2/BCL6 AND POOR OUTCOME FOR EBER-ISH POSITIVE PATIENTS C. Keane et al., Brisbane (Australia)
18:20	087	THE MOLECULAR HISTORY OF RICHTER SYNDROME D. Rossi et al., Novara (Italy)
15:50-18:30		<b>SESSION 9 – PEDIATRIC LYMPHOMA</b> (room C) Chair: S. Morris, Memphis, TN (USA) and A. Reiter, Giessen (DE)
15:50	088	WITH THE LMB AND BFM PROTOCOLS, CHILDREN AND ADOLESCENTS WITH B-CELL NON HODGKIN'S LYMPHOMA AND MATURE B-CELL LEUKEMIA HAVE SIMILAR SURVIVAL C. Patte et al., Villejuif (France)
16:05	089	IN CHILDHOOD B-CELL NON HODGKIN'S LYMPHOMA (B-NHL) AND MATURE B-CELL ACUTE LEUKEMIA (B-AL) WITH CNS DISEASE AT DIAGNOSIS, PATIENTS WITH BLASTS IN CSF ARE AT HIGHER RISK OF EVENT V. Minard-Colin et al., Villejuif (France)
16:17	090	SAFETY AND PHARMACOKINETICS (PK) OF RITUXIMAB (R) IN COMBINATION WITH FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS (C+A) WITH STAGE III/IV MATURE B-NHL: A CHILDREN'S ONCOLOGY GROUP REPORT M.J. Barth et al., Buffalo, NY (USA)
16:32	091	ANALYSIS OF TREATMENT FAILURE IN PATIENTS TREATED FOR NHL-B /B-ALL IN POLISH PEDIATRIC LEUKEMIA/LYMPHOMA STUDY GROUP E. Latos-Grazynska et al., Wroclaw (Poland)

16:47	092	EXCELLENT OUTCOME IN AGGRESSIVE NON HODGKIN'S LYMPHOMA IN ADOLESCENTS AND YOUNG ADULTS TREATED WITH CHOP-BASED REGIMENS IN DSHNHL TRIALS: AGE IS NOT A RISK FACTOR IN PATIENTS BELOW 50 YEARS L.H. Trümper et al., Göttingen (Germany)
17:02	093	ALK TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF NHL S. Morris, Memphis, TN (USA)
17:34	094	ANTI-ALK ANTIBODIES IN CHILDREN WITH LYMPHOMA WITH VARIANT ALK TRANSLOCATIONS C. Damm-Welk et al., Giessen (Germany)
17:45	095	MOLECULAR CHARACTERIZATION OF MATURE B-CELL LYMPHOMAS IN CHILDREN: A COOPERATIVE STUDY OF MMML AND THE NHL-BFM GROUP I. Salaverria et al., Kiel (Germany)
18:00	096	AMPLIFICATION OF CHROMOSOME 13Q31 IS ASSOCIATED WITH MIR-17 OVEREXPRESSION AND RELAPSE IN PEDIATRIC BURKITT LYMPHOMA R.R. Miles et al., Salt Lake City, UT (USA)
18:15	097	MINIMAL DISSEMINATED DISEASE/RESIDUAL DISEASE IN CHILDREN AND ADOLESCENTS WITH MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL) MAY IMPACT THE RISK OF RELAPSE: A CHILDREN'S ONCOLOGY GROUP REPORT B. Shiramizu et al., Honolulu, HI (USA)
17:30 – 18:20* *except for		<b>FOCUS ON... SESSIONS</b> (4 parallel sessions)
17:30 – 18:30*		<b>HIGH-DOSE CHEMOTHERAPY</b> (room A) Chair: D.C. Linch, London (UK)
17:30	098	THE NUMBER OF PREVIOUS TREATMENT LINES HAS NO IMPACT ON THE OUTCOME AFTER HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL RESCUE WITH BEAM FOR RELAPSED FOLLICULAR LYMPHOMA S. Montoto et al., London (UK)
17:40	099	AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR TRANSFORMED INDOLENT NON-HODGKIN LYMPHOMA: A REPORT OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP (CBMTG) D. Villa et al., Vancouver, B.C. (Canada)
17:50	100	AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) AS UPFRONT OR SALVAGE THERAPY FOR NON-CUTANEOUS T CELL LYMPHOMA (TCL): THE M.D. ANDERSON CANCER CENTER (MDACC) EXPERIENCE A. Beitinjaneh et al., Houston, TX (USA)
18:00	101	LONG TERM DISEASE CONTROL AND OVERALL SURVIVAL AFTER EARLY DOSE INTENSIFICATION IN T-NHL DEPEND ON SPECIFIC ENTITIES R. Marks et al., Freiburg (Germany)
18:10	102	UPDATE OF THE NORDIC MCL2 TRIAL UPDATE: 10-YEAR SURVIVAL 57% FOLLOWING INTENSIVE IMMUNOCHEMOTHERAPY AND ASCT, BUT LATE RELAPSES DO OCCUR C.H. Geisler et al., Copenhagen (Denmark)
18:20	103	TOTAL BODY IRRADIATION (TBI) IN THE CONDITIONING REGIMEN OF AUTOLOGOUS STEM CELL TRANSPLANTATION REDUCES THE RISK OF RELAPSE OF MANTLE CELL LYMPHOMA TRANSPLANTED IN PARTIAL REMISSION: A RETROSPECTIVE STUDY FROM THE LYMPHOMA WORKING PARTY OF THE EBMT O. Hermine et al., Paris (France)
17:30 – 18:20		<b>LYMPHOMA IN THE ELDERLY</b> (USI Auditorium, Lugano University) Chair: B. Coiffier, Pierre Bénite (France)
17:30	104	EBV POSITIVE DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY IS AN AGGRESSIVE B CELL NEOPLASM WITH A POST GERMINAL CENTER B CELL PHENOTYPE AND CHARACTERIZED BY NFKB PATHWAY ACTIVATION. EVALUATION OF A WESTERN SERIES OF 47 CASES S. Montes-Moreno et al., Madrid (Spain)
17:40	105	COMPREHENSIVE GERIATRIC ASSESSMENT-ADAPTED CHEMOTHERAPY IN ELDERLY PATIENTS (> 70 YEARS) WITH DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA (DLBCL): FINAL RESULTS AND LONG TERM FOLLOW-UP M. Spina et al., Aviano (Italy)
17:50	106	R-CHOP14 COMPARED TO R-CHOP21 IN ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF THE SECOND INTERIM ANALYSIS OF THE LNH03-6B GELA STUDY R. Delarue et al., Paris (France)
18:00	107	EFFICACY AND TOLERABILITY OF ABVD AND STANFORD V FOR ELDERLY ADVANCED-STAGE HODGKIN LYMPHOMA (HL): ANALYSIS FROM THE PHASE III RANDOMIZED US INTERGROUP TRIAL E2496 A.M. Evens et al., Worcester, MA (USA)
18:10	108	AUTOLOGOUS STEM CELL TRANSPLANT IS FEASIBLE IN VERY ELDERLY PATIENTS WITH LYMPHOMA AND LIMITED COMORBIDITY R.L. Elstrom et al., New York, NY (USA)
17:30 – 18:20		<b>NEW DRUG COMBINATIONS</b> (USI Aula Magna, Lugano University) Chair: J.W. Friedberg, Rochester, NY (USA)
17:30	109	ORAL LENALIDOMIDE PLUS 4 DOSES OF RITUXIMAB INDUCED PROLONGED REMISSIONS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMPLETED PHASE I/II CLINICAL TRIAL M. Wang et al., Houston, TX (USA)

17:40	110	COMBINATION OF LENALIDOMIDE WITH R-CHOP (R2CHOP) IS SAFE AND EFFECTIVE AS INITIAL THERAPY FOR AGGRESSIVE B-CELL LYMPHOMAS - A PHASE I/II STUDY G. Nowakowski et al., Rochester, MN (USA)
17:50	111	PHASE II TRIAL OF CISPLATIN PLUS ETOPOSIDE PLUS GEMCITABINE PLUS SOLUMEDROL (PEGS) IN PERIPHERAL T-CELL NON-HODGKIN LYMPHOMA (SWOG S0350) D. Mahadevan et al., Tucson, AZ (USA)
18:00	112	FINAL RESULTS OF A PHASE I-II CLINICAL TRIAL OF OXALIPLATIN, FLUDARABINE, CYTARABINE, AND RITUXIMAB (OFAR) COMBINATION THERAPY IN PATIENTS WITH AGGRESSIVE, RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND RICHTER SYNDROME (RS) A.M. Tsimberidou et al., Houston, TX (USA)
18:10	113	SHORT COURSE FLUDARABINE, MITOXANTRONE, RITUXIMAB FOLLOWED BY <sup>90</sup> Y-IBRITUMOMAB TIUXETAN IN UNTREATED INTERMEDIATE/HIGH-RISK FOLLICULAR LYMPHOMA: A PHASE II TRIAL P.L. Zinzani et al., Bologna (Italy)
17:30 – 18:20		<b>PLASMA CELL DISORDERS AND WALDENSTRÖM MACROGLOBULINEMIA</b> (Cittadella Theater) Chair: V. Rajkumar, Rochester, MN (USA)
17:30	114	CYTOGENETIC ABNORMALITIES IN A COHORT OF 175 PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA BEFORE TREATMENT: CLINICAL AND BIOLOGICAL CORRELATIONS F. Nguyen-Khac et al., Paris (France)
17:40	115	MICRORNA-9* REGULATES HISTONE ACETYLATION IN WALDENSTRÖM'S MACROGLOBULINEMIA A.M. Roccaro et al., Boston, MA (USA)
17:50	116	FAMILIAL DISEASE STATUS IS ASSOCIATED WITH AN INFERIOR TREATMENT OUTCOME IN PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA S.P. Treon et al., Boston, MA (USA)
18:00	117	RESPONSES TO SINGLE-AGENT CARFILZOMIB (CFZ) ARE NOT AFFECTED BY CYTOGENETICS IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (R/R MM) A.J. Jakubowiak et al., Ann Arbor, MI (USA)
18:10	118	IL-6 MEDIATED HEMATOPOIESIS DEVIATION FAVORS APRIL PRODUCTION DURING MULTIPLE MYELOMA INVASION OF BONE MARROW B. Huard et al., Geneva (Switzerland)
19:00 – 21:00 (parallel symposia)		SEATTLE GENETICS and MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY <b>EVOLUTION OF MAb TECHNOLOGY IN LYMPHOMAS</b> (room B I) Chair : F. Cavalli, Bellinzona (Switzerland)
		CELGENE <b>EXTENDING RESPONSE DURATION IN LYMPHOMAS: THE ROLE OF EMERGING NEW TREATMENTS</b> (room BII) Chairs: B. Coiffier, Pierre Bénite, Lyon (France) and M. Czuczman, New York, NY (USA)

## Friday, June 17, 2011

---

08:00 – 08:30		POSTER SET UP II (Marquee Parco Ciani)
08:30 – 18:30		<b>POSTER SESSION II *</b> (Marquee Parco Ciani) * <i>printing of the posters sponsored by Mundipharma</i> <i>Authors present during lunch time</i>
	270-281	PEDIATRIC LYMPHOMA
	282-294	HODGKIN LYMPHOMA
	295-319	INDOLENT LYMPHOMA
	320-345	AGGRESSIVE LYMPHOMA
	346-361	NEW DRUGS
08:00 - 08:45		<b>MEET THE PROFESSOR</b> (repetition of some of Wednesday sessions)
	VI	<b>MICRO-ARRAYS FOR DUMMIES</b> (room A) M.F. Fey, Berne (Switzerland)
	XV	PRIMARY CUTANEOUS LYMPHOMAS (room B I) R. Willemze, Leiden (Netherlands)
	XI	DISTINGUISHING BURKITT LYMPHOMA FROM DIFFUSE LARGE B-CELL LYMPHOMA (room B II) A. Jack, Leeds (UK)
	VII	THE ROLE OF THE MICROENVIRONMENT IN LYMPHOID CANCERS (USI Auditorium, Lugano University) R.D. Gascoyne, Vancouver, B.C. (Canada)
	XIII	THE ROLE OF IMMUNOTHERAPY IN THE TREATMENT OF LYMPHOMA (USI Aula Magna, Lugano University) R. Levy, Stanford, CA (USA)
	XIV	T AND NK CELL LYMPHOPROLIFERATIVE DISORDERS (Cittadella Theater) S.T. Rosen, Chicago, IL (USA)

09:00 - 10:30		<b>SESSION 10 – CLL</b> (room A, B, C and Marquee Parco Ciani) Chair: B.D. Cheson, Washington, D.C. (USA) and J. Gribben, London (UK)
09:00	119	DEL(13Q14.3) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH 13Q DELETION ALONE OR NORMAL KARYOTYPE F. Bertoni et al., Bellinzona (Switzerland)
09:15	120	RITUXIMAB PLUS CHLORAMBUCIL (R-CHLORAMBUCIL) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): FINAL ANALYSIS OF AN OPEN-LABEL PHASE II STUDY P. Hillmen et al., Leeds (UK)
09:30	121	FCR VS AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A COMPARISON OF TWO PROSPECTIVE STUDIES OF THE GCLLSG P. Dreger et al., Heidelberg (Germany)
09:45	122	THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND TOLERABLE IN PATIENTS WITH POOR-RISK CLL: INTERIM RESULTS FROM A PHASE IB/II STUDY S. O'Brien et al., Houston, TX (USA)
10:00	123	SEQUENTIAL THERAPY OF FLUDARABINE, MITOXANTRONE AND CYCLOPHOSPHAMIDE (FMC) INDUCTION FOLLOWED BY ALEMTUZUMAB CONSOLIDATION IS EFFECTIVE AND SAFE IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) - RESULTS FROM A MULTICENTER PHASE II TRIAL OF THE GERMAN CLL STUDY GROUP G. Hopfinger et al., Salzburg (Austria)
10:15	124	CLADRIBINE GIVEN SUBCUTANEOUSLY FOR FIVE DAYS HAS EQUIVALENT EFFICACY TO AND LOWER TOXICITY THAN CLADRIBINE GIVEN FOR SEVEN CONSECUTIVE DAYS IN PATIENTS WITH HAIRY CELL LEUKEMIA F. Forconi et al., Siena (Italy)
09:00 - 10:30		<b>"CASE DISCUSSION" SESSIONS</b> (3 parallel sessions: room B I, B II, USI Auditorium)  AGGRESSIVE LYMPHOMA (room B I) Chair: C. Geisler, Copenhagen (Denmark) – Presenter: L. Sehn, Vancouver, B.C. (Canada) Discussants: J.F. Seymour, Melbourne (Australia) and M.A. Shipp, Boston, MA (USA)  INDOLENT LYMPHOMA (room B II) Chair: J.W. Friedberg, Rochester, NY (USA) – Presenter: M.H. van Oers, Amsterdam (Netherlands) Discussants: M. Rummel, Giessen (Germany) and G. Salles, Pierre Bénite (France)  EXTRANODAL LYMPHOMA (USI Auditorium, Lugano University) Chair: M.K. Gospodarowicz, Toronto (Canada) – Presenter: M.-J. Kersten, Amsterdam (Netherlands) Discussants: A. Lopez-Guillermo, Barcelona (Spain) and E. Zucca, Bellinzona (Switzerland)
10:30 - 10:50		<b>COFFEE BREAK</b> (Marquee Parco Ciani)
10:50 - 12:05		<b>SESSION 11 - T-CELL LYMPHOMA</b> (room A, B, C and Marquee Parco Ciani) Chair: M. Federico, Modena (Italy) and J.M. Vose, Omaha, NE (USA)
10:50	125	DURABLE REMISSIONS WITH SGN-35 (BRENTUXIMAB VEDOTIN): UPDATED RESULTS OF A PHASE 2 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL) A. Shustov et al., Seattle, WA (USA)
11:05	126	PRELIMINARY RESULTS FROM AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF BENDAMUSTINE IN RELAPSED OR REFRACTORY T-CELL LYMPHOMA FROM THE FRENCH GOELAMS GROUP: THE BENTLY TRIAL G. Damaj et al., Amiens (France)
11:20	127	LONG-TERM OUTCOME OF ADULTS WITH SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA TREATED WITHIN THE GROUPE D'ETUDE DES LYMPHOMES DE L'ADULTE (GELA) TRIALS D. Sibon et al., Paris (France)
11:35	128	CHOEP-14 AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: PROSPECTIVE STUDY BY THE NORDIC LYMPHOMA GROUP (NLG-T-01) G.F. Lauritzen et al., Oslo (Norway)
11:50	129	ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA: CLINICAL AND HISTOLOGICAL FINDINGS FROM THE INTERNATIONAL PERIPHERAL T-CELL LYMPHOMA PROJECT J.M. Delabie et al., Oslo (Norway)
12:05-13:00		<b>LUNCH AND POSTER VIEWING</b> (Marquee Parco Ciani)
13:00-13:55	003	<b>ULTMANN LECTURE</b> sponsored by ASCO (room A, B, C and Marquee Parco Ciani) TREATMENT OF MYELOMA: CURE VERSUS CONTROL V. Rajkumar, Rochester, MN (USA) Chair: J.O. Armitage, Omaha, NE (USA)
13:55-15:00		<b>SESSION 12 – LYMPHOMA AND APOPTOSIS</b> (room A and Marquee Parco Ciani) Chair: O.A. O'Connor, New York, NY (USA)
13:55	130	Introductory lecture: O.A. O'Connor, New York, NY (USA)
14:15	131	ACTIVATION OF THE STAT3 SIGNALING PATHWAY PREDICTS POOR SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH R-CHOP

		K. Fu et al., Omaha, NE (USA)
14:30	132	METABOLIC TARGETING IN LYMPHOMA THERAPY C.A. Schmitt et al., Berlin (Germany)
14:45	133	A CYCLIN-D1 INTERACTION WITH BAX UNDERLIES ITS ONCOGENIC ROLE AND POTENTIAL AS A THERAPEUTIC TARGET IN MANTLE CELL LYMPHOMA J.A. Martinez-Ciiment et al., Pamplona (Spain)
15:00 – 15:20		<b>COFFEE BREAK</b> (Marquee Parco Ciani)
15:20 - 16:35		<b>SESSION 13 – INDOLENT LYMPHOMA</b> (room A, B, C and Marquee Parco Ciani) Chair: S. Montoto, London (UK) and E. Zucca, Bellinzona (Switzerland)
15:20	134	INTERNATIONAL PHASE III STUDY OF CHLORAMBUCIL VERSUS FLUDARABINE AS INITIAL THERAPY FOR WALDENSTROM'S MACROGLOBULINEMIA AND RELATED DISORDERS:RESULTS IN 414 PATIENTS ON BEHALF OF FCGCLL/WM, GOELAMS, GELA AND NCRI V. Leblond et al., Paris (France)
15:35	135	R-CVP VS R-CHOP VS R-FM FOR THE INITIAL TREATMENT OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS OF FOLLO5 IIL TRIAL M. Federico et al., Modena (Italy)
15:50	136	RITUXIMAB (R) IN COMBINATION WITH INTERFERON-A2A (IFN) SHOWS BETTER RESPONSE THAN SINGLE R IN PATIENTS WITH FOLLICULAR OR OTHER CD20+ LOW-GRADE (INDOLENT) LYMPHOMA. A RANDOMIZED PHASE III STUDY FROM THE NORDIC LYMPHOMA GROUP E. Kimby et al., Stockholm (Sweden)
16:05	137	LENALIDOMIDE PLUS RITUXIMAB IS A HIGHLY EFFECTIVE AND WELL-TOLERATED BIOLOGIC THERAPY IN UNTREATED INDOLENT B CELL NON-HODGKINS LYMPHOMA N. Fowler et al., Houston, TX (USA)
16:20	138	HEMATOLOGICAL RESPONSE TO ANTIVIRAL TREATMENT IN 94 PATIENTS WITH INDOLENT B-CELL LYMPHOMAS ASSOCIATED WITH HEPATITIS C VIRUS INFECTION: A STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL) L. Arcaini et al., Pavia (Italy)
16:35 - 17:10	139-140	<b>CONTROVERSY II: IS INTERIM PET USEFUL IN PLANNING TREATMENT FOR DLBCL?</b> (room A, B, C and Marquee Parco Ciani) C. Haioun, Creteil Cedex (France) vs C. Moskowitz, New York, NY (USA) Chair: A. Gallamini, Cuneo (Italy)
17:10 – 17:30		<b>REPORT OF THE 11-ICML CLOSED WORKSHOP</b> (room A, B, C and Marquee Parco Ciani) T.A. Lister, London (UK)
17:30 - 18:30		<b>FAREWELL APERITIF</b> (Marque Parco Ciani)
18:30 - 20:30 (symposium)		MUNDIPHARMA <b>OPTIMISING THERAPY IN THE ELDERLY MULTIPLE MYELOMA PATIENT</b> (room B I) Chairs: H. Ludwig, Wien (Austria) and A. Palumbo, Turin (Italy)

## Saturday, June 18, 2011

---

08:00 - 08:50		<b>FOCUS ON... SESSIONS</b> (2 parallel sessions)
08:00 - 08:50		<b>MONOCLONAL ANTIBODIES</b> (room A) Chair: R. Levy, Stanford, CA (USA)
08:00	141	LYMPHOMA PATIENTS TREATED WITH RITUXIMAB-CONTAINING REGIMENS DO NOT ACHIEVE PROTECTIVE SEROLOGICAL RESPONSES TO H1N1 INFLUENZA VIRUS AFTER VACCINATION O.E. Yri et al., Oslo (Norway)
08:10	142	FC $\gamma$ R POLYMORPHISMS DO NOT INFLUENCE RESPONSE TO RITUXIMAB IN ASYMPTOMATIC, NON-BULKY FOLLICULAR LYMPHOMA; RESULTS FROM INTERGROUP TRIAL OF RITUXIMAB VS "WATCH AND WAIT" L. Lowry et al., London (UK)
08:20	143	FC GAMMA RECEPTOR IIB ON HUMAN B CELLS PROMOTES RITUXIMAB INTERNALIZATION AND REDUCES CLINICAL EFFICACY S.H. Lim et al., Southampton (UK)
08:30	144	RESULTS FROM A PHASE II STUDY (BO20999) OF RO5072759 (GA101) MONOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA G. Cartron et al., Montpellier (France)
08:40	145	A PHASE 2B TRIAL COMPARING DACETUZUMAB + R-ICE VS PLACEBO + R-ICE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA L. Fayad et al., Houston, TX (USA)
08:00 - 08:50		<b>PRIMARY MEDIASTINAL BCL</b> (room B) Chair: C. Thieblemont, Paris (France)
08:00	146	BORTEZOMIB (BTZ), IKK INHIBITOR ML120B, AND COMBINATION THERAPY INDUCE APOPTOSIS, INHIBIT NF- $\kappa$ B ACTIVATION, AND DECREASE SPECIFIC PROTEINS IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) R.R. Miles et al., Salt Lake City, UT (USA)

08:10	147	PET/CT RESPONSE ANALYSIS IN PRIMARY MEDIASTINAL DIFFUSE LARGE B-CELL LYMPHOMA (PMBL): PRELIMINARY RESULTS OF THE IELSG-26 STUDY L. Ceriani et al., Bellinzona (Switzerland)
08:20	148	THE IMPACT OF R-VACOP-B AND THE PROGNOSTIC SIGNIFICANCE OF INTERIM FDG-PET/CT ON THE OUTCOME OF PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA- A RETROSPECTIVE ANALYSIS OF A SINGLE CENTER COHORT A. Avigdor et al., Tel-Hashomer (Israel)
08:30	149	MACOP-B+/- RITUXIMAB FOLLOWED BY INVOLVED MEDIASTINAL RADIOTHERAPY IS A SAFE AND HIGH EFFECTIVE THERAPY FOR PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA (PMBL): LONG TERM RESULTS AND LATE TOXICITY FROM A SINGLE ITALIAN CENTER M. Martelli et al., Rome (Italy)
08:40	150	UNTREATED PRIMARY MEDIASTINAL B-CELL (PMBL) AND MEDIASTINAL GREY ZONE (MGZL) LYMPHOMAS: COMPARISON OF BIOLOGICAL FEATURES AND CLINICAL OUTCOME FOLLOWING DA-EPOCH-R WITHOUT RADIATION K. Dunleavy et al., Bethesda MD (USA)
08:00 -18:00		<b>WORKSHOP: "ESMO CONSENSUS CONFERENCE ON LYMPHOMA"</b> (Closed - room C) Chairs: M. Dreyling, Munich (Germany) and M. Ghilmini, Bellinzona (Switzerland)
08:55-11:00		<b>SESSION 14 - SIGNALLING PATHWAYS IN LYMPHOMA</b> (room A) Chair: F.E. Cotter, London (UK) and M.A. Shipp, Boston, MA (USA)
08:55	151	Introductory lecture: M.A. Shipp, Boston, MA (USA)
09:15	152	MULTICENTER PHASE II TRIAL OF MLN8237, AN INVESTIGATIONAL INHIBITOR OF AURORA A KINASE (AAK), IN PATIENTS (PTS) WITH AGGRESSIVE B-CELL AND T-CELL NON-HODGKIN LYMPHOMA (NHL) J.W. Friedberg et al., Rochester, NY (USA)
09:30	153	THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND WELL TOLERATED IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES: FINAL RESULTS FROM A PHASE I STUDY R.H. Advani et al., Stanford, CA (USA)
09:45	154	PIM INHIBITION AS A RATIONAL THERAPEUTIC APPROACH IN DIFFUSE LARGE B-CELL LYMPHOMA C. Gómez-Abad et al., Madrid (Spain)
10:00	155	TARGETING CAP-DEPENDENT TRANSLATION TO BYPASS PRO-SURVIVAL SIGNALING BY AKT AND THE PIM FAMILY KINASES IN NON-HODGKIN LYMPHOMA J.H. Schatz et al., New York, NY (USA)
10:15	156	A NOVEL SMALL MOLECULE MEK INHIBITOR INDUCES CELL DEATH THROUGH A BIM-DEPENDENT MECHANISM IN NON-HODGKIN LYMPHOMA (NHL) CELL LINES, PRIMARY CELLS, AND A HUMAN NHL XENOGRAFT MODEL A.M. Evens et al., Worcester, MA (USA)
10:30	157	PHASE 1 STUDY OF A NOVEL ORAL JAK2 INHIBITOR, SB1518, IN PATIENTS WITH RELAPSED LYMPHOMA: EVIDENCE OF CLINICAL AND BIOLOGIC ACTIVITY IN MULTIPLE LYMPHOMA SUBTYPES A. Younes et al., Houston, TX (USA)
10:45	158	A PHASE 1 STUDY OF CAL-101, AN ISOFORM-SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110D, IN COMBINATION WITH ANTI-CD20 MONOCLONAL ANTIBODY THERAPY AND/OR BENDAMUSTINE IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES J.P. Leonard et al., New York, NY (USA)
09:00 – 11:00		<b>SESSION 15 – HODGKIN LYMPHOMA</b> (room B) Chair: G.P. Canellos, Boston, MA (USA) and M. Engert, Cologne (Germany)
09:00	159	GENETIC POLYMORPHISMS INFLUENCE THE RISK OF HODGKIN'S LYMPHOMA O.E. Yri et al., Oslo (Norway)
09:15	160	DURABLE COMPLETE REMISSIONS IN A PIVOTAL PHASE 2 STUDY OF SGN-35 (BRENTUXIMAB VEDOTIN) IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL) A. Younes et al., Houston, TX (USA)
09:30	161	BIOMARKER ANALYSIS OF PIVOTAL PHASE II STUDY OF ORAL PANOBINOSTAT (PAN) IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) S. Harrison et al., Melbourne (Australia)
09:45	162	EARLY DETERMINATION OF TREATMENT SENSITIVITY IN HODGKIN LYMPHOMA: FDG-PET/CT AFTER ONE CYCLE OF THERAPY HAS A HIGHER NEGATIVE PREDICTIVE VALUE THAN AFTER TWO CYCLES OF CHEMOTHERAPY M. Hutchings et al., Copenhagen (Denmark)
10:00	163	MULTICENTRE CLINICAL STUDY WITH EARLY TREATMENT INTENSIFICATION IN HIGH-RISK HODGKIN LYMPHOMA (HL) PATIENTS, WITH A POSITIVE FDG-PET SCAN AFTER TWO ABVD COURSES – GITIL HD0607 STUDY A. Gallamini et al., Cuneo (Italy)
10:15	164	IGEV VS. IGEV+BORTEZOMIB (VELCADE™) BEFORE HIGH-DOSE CONSOLIDATION THERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL): A RANDOMIZED PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI M. Balzarotti et al., Rozzano Milano (Italy)
10:30	165	PARENTHOOD IN SURVIVORS OF HODGKIN LYMPHOMA (HL): AN EORTC-GELA GENERAL POPULATION CASE-CONTROL STUDY

M.A. van der Kaaij et al., Groningen (Netherlands)

10:45 166 GONADAL FUNCTION IN WOMEN AFTER TREATMENT OF EARLY UNFAVOURABLE HODGKIN LYMPHOMA (HL). FIRST RESULTS OF THE FERTILITY RESEARCH PROJECT WITHIN THE 5th TRIAL GENERATION, GERMAN HODGKIN STUDY GROUP (GHSG)  
K. Behringer et al., Cologne (Germany)

11:00 **CLOSING REMARKS** (room A and B)  
Chair: F. Cavalli, Bellinzona (Switzerland)  
J.O. Armitage, Omaha, NE (USA)

## GENERAL INFORMATION

### Participants are credited with :

- 21 European CME credits (ECMEC)
- 25 Category 1 ESMO-MORA points
- European endorsement of ECMEC by the UEMS/EACCME has been requested
- ECMEC credits are recognized by the American Medical Association (AMA) and become valid credit towards the Physicians Recognition Award (PRA) in the United States.

### REGISTRATION DESK :

Monday, June 13: only by appointments, only for groups  
Tuesday, June 14: 08:30 – 19:00  
from Wednesday, June 15, to Friday, June 17: 07:30 – 19:00  
Saturday, June 18: 07:30 – 12:00  
Tel: +41 (0)58 866 66 68  
Fax: +41 (0)58 866 66 39  
e-mail: cristiana.brentan@lymphcon.ch  
orietta.lugli@lymphcon.ch

The following services will be available in Palazzo dei Congressi:  
bank and exchange service,  
internet corner, sponsored by Millennium: The Takeda Oncology Company  
slide preview point,  
transport info desk, for information on public transports and buses organized by 11-ICML Secretariat.

### Free Internet Wi-Fi access is available for conference delegates throughout the venue.

To access Wi-Fi, please use the following information:

Network name: 11-ICML

password: WelcometotherealWorld-11-ICML

## Acknowledgements

**The conference organizers wish to thank the following sponsors for their financial support:**

Affymetrix  
Amgen Oncology  
Astra Zeneca  
Baxter  
Bristol-Myers Squibb SA  
Celgene International Sàrl  
Celltrion Healthcare Co., Ltd.  
Center of Excellence Media  
F. Hoffmann-La Roche Limited  
GlaxoSmithKline AG  
Helsinn Healthcare SA  
Hematology Times  
Janssen, Pharmaceutical Companies of Johnson & Johnson  
Lilly Oncology  
Merck Sharp & Dohme  
Millennium: The Takeda Oncology Company  
Mundipharma International Limited  
Novartis  
OrPha Swiss  
Pfizer  
priME Oncology  
Pierre Fabre  
Seattle Genetics

**The conference organizers wish to thank the following contributors for their support:**

American Society of Clinical Oncology (ASCO)  
Banca dello Stato del Canton Ticino  
City of Lugano  
Comunità Tariffale Ticino e Moesano  
European School of Oncology (ESO)  
European Society for Medical Oncology (ESMO)  
Hotel Splendide Royal  
Swiss Academy of Medical Sciences (SAMS)  
Swiss Cancer League  
Swiss International Air Lines Ltd.

## SAVE THE DATE :

**12-ICML**

**June 19-22, 2013**

**Lugano, Switzerland**